NCT06744504View on ClinicalTrials.gov

Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1

PHASE3RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 10, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2029

Conditions
AMLRUNX1-RUNX1T1 Fusion Protein Expression
Interventions
DRUG

cytarabine

Cytarabine combined with daunorubicin was used for induction therapy. According to the different doses of cytarabine, it was divided into standard dose group and intermediate dose group.In addition, high doses of cytarabine are also used for post-remission treatment.

DRUG

daunorubicin

combined with cytarabine and used for induction therapy

DRUG

idarubicin

combined with cytarabine and cyclophosphamide and used for post-remission treatment

DRUG

cyclophosphamide

combined with cytarabine and idarubicin and used for post-remission treatment

Trial Locations (1)

300020

RECRUITING

Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER